1 Li, Y. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399, 2047-2064 (2022). https://doi.org:10.1016/S0140-6736(22)00478-0
2 Busack, B. & Shorr, A. F. Going Viral-RSV as the Neglected Adult Respiratory Virus. Pathogens 11 (2022). https://doi.org:10.3390/pathogens11111324
3 Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102, 531-537 (1998).
4 Caserta, M. T., O'Leary, S. T., Munoz, F. M., Ralston, S. L. & Committee On Infectious, D. Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics 152 (2023). https://doi.org:10.1542/peds.2023-061803
5 Feltes, T. F. et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143, 532-540 (2003). https://doi.org:10.1067/s0022-3476(03)00454-2
6 Phuah, J. Y. et al. Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomed Pharmacother 169, 115851 (2023). https://doi.org:10.1016/j.biopha.2023.115851
7 Kampmann, B. et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med 388, 1451-1464 (2023). https://doi.org:10.1056/NEJMoa2216480
8 Melgar, M. et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 72, 793-801 (2023). https://doi.org:10.15585/mmwr.mm7229a4
9 Griffiths, C., Drews, S. J. & Marchant, D. J. Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev 30, 277-319 (2017). https://doi.org:10.1128/CMR.00010-16
10 Zlateva, K. T., Lemey, P., Moes, E., Vandamme, A. M. & Van Ranst, M. Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein. J Virol 79, 9157-9167 (2005). https://doi.org:10.1128/JVI.79.14.9157-9167.2005
11 Elawar, F. et al. A Virological and Phylogenetic Analysis of the Emergence of New Clades of Respiratory Syncytial Virus. Sci Rep 7, 12232 (2017).
12 Yu, J. M., Fu, Y. H., Peng, X. L., Zheng, Y. P. & He, J. S. Genetic diversity and molecular evolution of human respiratory syncytial virus A and B. Sci Rep 11, 12941 (2021). https://doi.org:10.1038/s41598-021-92435-1
13 Utokaparch, S. et al. The relationship between respiratory viral loads and diagnosis in children presenting to a pediatric hospital emergency department. Pediatr Infect Dis J 30, e18-23 (2011). https://doi.org:10.1097/INF.0b013e3181ff2fac
14 Rebuffo-Scheer, C. et al. Whole genome sequencing and evolutionary analysis of human respiratory syncytial virus A and B from Milwaukee, WI 1998-2010. PLoS One 6, e25468 (2011). https://doi.org:10.1371/journal.pone.0025468
15 Simoes, E. A. F. et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis 73, e4400-e4408 (2021). https://doi.org:10.1093/cid/ciaa951
16 McLellan, J. S. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol 11, 70-75 (2015). https://doi.org:10.1016/j.coviro.2015.03.002
17 McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592-598 (2013). https://doi.org:10.1126/science.1243283
18 McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013). https://doi.org:10.1126/science.1234914
19 McLellan, J. S., Yang, Y., Graham, B. S. & Kwong, P. D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85, 7788-7796 (2011). https://doi.org:10.1128/JVI.00555-11
20 Griffiths, C. D. et al. IGF1R is an entry receptor for respiratory syncytial virus. Nature 583, 615-619 (2020). https://doi.org:10.1038/s41586-020-2369-7
21 Hayes, R. S., Oraby, A. K., Camargo, C., Marchant, D. J. & Sagan, S. M. Mapping respiratory syncytial virus fusion protein interactions with the receptor IGF1R and the impact of alanine-scanning mutagenesis on viral infection. J Gen Virol 105 (2024). https://doi.org:10.1099/jgv.0.001951
22 Bin, L. et al. Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17. Sci Rep 9, 3898 (2019). https://doi.org:10.1038/s41598-019-40387-y
23 McCool, R. S. et al. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope. J Virol, e0092923 (2023). https://doi.org:10.1128/jvi.00929-23
24 Mas, V., Nair, H., Campbell, H., Melero, J. A. & Williams, T. C. Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset. Vaccine 36, 6660-6673 (2018). https://doi.org:10.1016/j.vaccine.2018.09.056
25 Rezende, W., Neal, H. E., Dutch, R. E. & Piedra, P. A. The RSV F p27 peptide: current knowledge, important questions. Front Microbiol 14, 1219846 (2023). https://doi.org:10.3389/fmicb.2023.1219846
26 Rezende, W. et al. The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent. J Virol 97, e0025423 (2023). https://doi.org:10.1128/jvi.00254-23
27 Jones, H. G. et al. Alternative conformations of a major antigenic site on RSV F. PLoS Pathog 15, e1007944 (2019). https://doi.org:10.1371/journal.ppat.1007944
28 Mukhamedova, M. et al. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity 54, 769-780 e766 (2021). https://doi.org:10.1016/j.immuni.2021.03.004
29 Zhao, X., Chen, F. P. & Sullender, W. M. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 318, 608-612 (2004). https://doi.org:10.1016/j.virol.2003.10.018
30 Atienza, B. J. P. et al. Dual Catalytic Synthesis of Antiviral Compounds Based on Metallocarbene-Azide Cascade Chemistry. J Org Chem (2018). https://doi.org:10.1021/acs.joc.8b00222
31 Hashimoto, K. & Hosoya, M. Neutralizing epitopes of RSV and palivizumab resistance in Japan. Fukushima J Med Sci 63, 127-134 (2017). https://doi.org:10.5387/fms.2017-09
32 Hause, A. M. et al. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS One 12, e0175792 (2017). https://doi.org:10.1371/journal.pone.0175792
33 Gilman, M. S. A. et al. Transient opening of trimeric prefusion RSV F proteins. Nat Commun 10, 2105 (2019). https://doi.org:10.1038/s41467-019-09807-5
34 Techaarpornkul, S., Barretto, N. & Peeples, M. E. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol 75, 6825-6834 (2001). https://doi.org:10.1128/JVI.75.15.6825-6834.2001
35 Techaarpornkul, S., Collins, P. L. & Peeples, M. E. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology 294, 296-304 (2002). https://doi.org:10.1006/viro.2001.1340
S0042682201913406 [pii]
36 Kim, Y. I. et al. Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children. Pediatr Res 78, 380-388 (2015). https://doi.org:10.1038/pr.2015.122
37 Rijsbergen, L. C. et al. Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures. mSphere 6 (2021). https://doi.org:10.1128/mSphere.00237-21
38 Zhu, Q. et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 9 (2017). https://doi.org:10.1126/scitranslmed.aaj1928
39 Wilkins, D. et al. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data. Lancet Infect Dis 23, 856-866 (2023). https://doi.org:10.1016/S1473-3099(23)00062-2
40 Grad, Y. H. et al. Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure. J Virol 88, 7286-7293 (2014). https://doi.org:10.1128/JVI.00038-14
41 Wu, E. Y. et al. A conservative isoleucine to leucine mutation causes major rearrangements and cold sensitivity in KlenTaq1 DNA polymerase. Biochemistry 54, 881-889 (2015). https://doi.org:10.1021/bi501198f
42 Bilawchuk, L. M., Griffiths, C. D., Jensen, L. D., Elawar, F. & Marchant, D. J. The Susceptibilities of Respiratory Syncytial Virus to Nucleolin Receptor Blocking and Antibody Neutralization are Dependent upon the Method of Virus Purification. Viruses 9 (2017). https://doi.org:10.3390/v9080207
43 Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6, 343-345 (2009). https://doi.org:10.1038/nmeth.1318
44 Pickett, B. E. et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res 40, D593-598 (2012). https://doi.org:10.1093/nar/gkr859
45 Shen, W., Le, S., Li, Y. & Hu, F. SeqKit: A Cross-Platform and Ultrafast Toolkit for FASTA/Q File Manipulation. PLoS One 11, e0163962 (2016). https://doi.org:10.1371/journal.pone.0163962
46 Madeira, F. et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res 47, W636-W641 (2019). https://doi.org:10.1093/nar/gkz268
47 Waterhouse, A. M., Procter, J. B., Martin, D. M., Clamp, M. & Barton, G. J. Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189-1191 (2009). https://doi.org:10.1093/bioinformatics/btp033
48 Harder, E. et al. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. J Chem Theory Comput 12, 281-296 (2016). https://doi.org:10.1021/acs.jctc.5b00864
49 Roe, D. R. & Cheatham, T. E., 3rd. PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. J Chem Theory Comput 9, 3084-3095 (2013). https://doi.org:10.1021/ct400341p